Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best young stocks with huge upside potential.
Lexeo Therapeutics Inc. (LXEO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Balyasny Asset Management Dmitry Balyasny | 4,009,137 | $16,116,731 | 0.02% | |
| 2. | Citadel Investment Group Ken Griffin | 3,607,967 | $14,504,027 | +33% | 0% |
| 3. | Vestal Point Capital Ryan Wilder | 3,228,161 | $12,977,207 | +185% | 0.68% |
| 4. | Millennium Management Israel Englander | 2,836,292 | $11,401,894 | +165% | 0.01% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,572,162 | $10,340,091 | +208% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.99 | 15,000 | $104,851.50 | 30,627 | 2024-11-25 | Filing | |
| $11.00 | 454,545 | $4,999,995.00 | 2,157,623 | 2023-11-07 | Filing | |
| $11.00 | 227,272 | $2,499,992.00 | 1,835,959 | 2023-11-07 | Filing | |
| $11.00 | 454,545 | $4,999,995.00 | 2,567,100 | 2023-11-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.56 | 44 | $420.68 | 65,862 | 2025-10-17 | Filing | |
| $8.94 | 3,844 | $34,346.14 | 65,906 | 2025-10-17 | Filing | |
| $9.56 | 40 | $382.44 | 68,930 | 2025-10-17 | Filing | |
| $8.94 | 3,486 | $31,147.41 | 68,970 | 2025-10-17 | Filing | |
| $9.56 | 24 | $229.46 | 64,197 | 2025-10-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,319 | $75,158 | 0% | |
| 2. | 124 | $823 | 0% | |
| 3. | 18,864 | $125 | 0% |
News See All
12 Best Young Stocks with Huge Upside Potential
On September 15, Tom Sosnoff, Tastylive founder, joined 'Squawk Box' on CNBC to discuss the state of the IPO landscape and what to make of the surge of IPO offerings.
Lexeo Therapeutics' Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy Designation
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best IPO stocks to buy according to Wall Street analysts.
13 Best IPO Stocks to Buy According to Wall Street Analysts
On August 14, Tony Kim, Centerview Partners co-president, joined CNBC's 'Closing Bell: Overtime' to discuss the IPO market and the dealmaking environment.
11 Best New Penny Stocks to Buy Right Now
On July 28, the Opening Bid team at Yahoo Finance and Victoria Fernandez, chief market strategist at Crossmark Global Investments, discussed the rise in cheap stock trading and what it can mean for the...